Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Pancreatic cancer, which has a poor prognosis, is becoming increasingly common in industrialized countries. Chemotherapy is the main treatment available for metastatic disease. Response to chemotherapy is currently assessed using imaging to monitor changes in the size of lesions undergoing treatment. Radiomics is a new method of analyzing quantitative data extracted from imaging that can be used to develop prediction algorithms and evaluate response to treatment. There is little robust radiomics data available for evaluating response to first-line treatments for pancreatic adenocarcinoma. Our main hypothesis is that quantifying tumor-related architectural changes could enable early identification of patients who will not respond to chemotherapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2024-01-09
Completion Date
2026-12
Last Updated
2025-11-21
Healthy Volunteers
No
Interventions
Patients treated with FOLFOX or FOLFIRINOX in first line
Treatment with FOLFOX or FOLFIRINOX (chemotherapy protocols) in first line
Patients treated with GEMCITABINE in first line
Treatment with GEMCITABINE (chemotherapy protocols) in first line
Locations (1)
Hôpital Cochin
Paris, France